David Langdon Yowe

This inventor holds 5 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignees: Novartis Ag, Irm LLC. Active years: 2014-2023.

USPTO Granted Patents = 5 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11802152 - Methods of treating FGF21-associated disorders (2023-10-31),

2. 11692046 - FGF21 mimetic antibodies and uses thereof (2023-07-04),

3. 11236159 - Methods of treating FGF21-associated disorders (2022-02-01),

4. 10899844 - FGF21 mimetic antibodies and uses thereof (2021-01-26),

5. 8710192 - PCSK9 antagonists (2014-04-29),

Title: The Innovative Journey of David Langdon Yowe

Introduction

David Langdon Yowe, an accomplished inventor based in Belmont, MA, has made significant contributions to the field of biotechnology. With a total of five patents to his name, he has focused his research on therapeutic interventions related to FGF21-associated disorders, demonstrating a strong commitment to advancing medical science.

Latest Patents

Among his notable inventions, his latest patents include innovative methods of treating FGF21-associated disorders. The present inventions relate to monoclonal antibodies and antigen-binding fragments that bind to human β-klotho, along with pharmaceutical compositions and methods of treatment comprising these elements. Notably, he has also developed FGF21 mimetic antibodies and their uses, further establishing his expertise in therapeutic antibodies for various applications.

Career Highlights

David's career has seen him working with prominent companies in the pharmaceutical industry, including Novartis AG and Irm LLC. His experiences in these organizations have provided him with valuable insights and skills that have greatly influenced his inventive work.

Collaborations

Throughout his career, David has collaborated with esteemed colleagues, including Regis Cebe and Brian R. Boettcher. These collaborations have contributed to the depth of knowledge and innovation in his projects, fostering a creative and effective research environment.

Conclusion

David Langdon Yowe continues to be a vital figure in the field of biotechnology. His innovative patents and collaborative approach to research affirm his dedication to improving health outcomes through scientific advancements. As he forges ahead, the impact of his work will undoubtedly resonate within the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.